跳转至内容
Merck

M3761

Supelco

甲硝唑

analytical standard

别名:

2-甲基-5-硝基咪唑-1-乙醇

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C6H9N3O3
CAS号:
分子量:
171.15
Beilstein:
611683
EC號碼:
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

analytical standard

品質等級

形狀

crystalline

技術

HPLC: suitable
gas chromatography (GC): suitable

mp

159-161 °C (lit.)

抗生素活性譜

Gram-negative bacteria
parasites

應用

forensics and toxicology
pharmaceutical (small molecule)

格式

neat

作用方式

DNA synthesis | interferes

儲存溫度

2-8°C

SMILES 字串

CC1=NC=C([N+]([O-])=O)N1CCO

InChI

1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3

InChI 密鑰

VAOCPAMSLUNLGC-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

甲硝唑(Metronidazole)是一种硝基咪唑类药物,尤其适合用于治疗由厌氧菌和原生动物引起的人类和家畜感染。

應用

此分析标准品可用于以下用途:
  • 碳糊电极 (CPE) 循环伏安法测定三种不同品牌甲硝唑片中甲硝唑的含量
  • 采用反相高效液相色谱-光电二极管阵列检测器(RP- HPLC-DAD)同时测定制药剂量的甲硝唑、二氯尼特、螺旋霉素和克利喹诺
  • 开发基于聚多巴胺/羧基多壁碳纳米管(MWCNTs-COOH)纳米复合材料的电化学传感器,测定甲硝唑
  • 液相色谱–离子阱质谱法(LC-MS/MS法分析在水、沉积物和鱼组织样本中的甲硝唑)
  • 基于多壁碳纳米管 (MWCNT) 和壳聚糖-镍络合物 (CTS-Ni) 的电化学传感器测定片剂、人尿液和血清样品中的甲硝唑

其他說明

有关合适的仪器技术的更多信息,请参阅产品′的检验报告。想要获得更多支持,请联系技术服务部。

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

Carc. 1B - Muta. 1B - STOT RE 2

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

dust mask type N95 (US), Eyeshields, Gloves


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Sonja Löfmark et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 50 Suppl 1, S16-S23 (2010-01-14)
Metronidazole has been used for the treatment of infections for >45 years and is still successfully used for the treatment of trichomoniasis, amoebiasis, and giardiasis. Anaerobic bacterial infections caused by Bacteroides species, fusobacteria, and clostridia respond favorably to metronidazole therapy.
Konstantinos Z Vardakas et al.
International journal of antimicrobial agents, 40(1), 1-8 (2012-03-09)
The objective of this review was to evaluate the frequency of treatment failure and recurrence of Clostridium difficile infection (CDI) following treatment with vancomycin or metronidazole in recently performed studies (last 10 years). Searches in PubMed and Scopus were performed
T H I Brummer et al.
BJOG : an international journal of obstetrics and gynaecology, 120(10), 1269-1276 (2013-06-22)
To evaluate cefuroxime and metronidazole antibiotic prophylaxis. Observational nonrandomised 1-year prospective cohort study. Fifty-three hospitals in Finland. A total of 5279 women undergoing hysterectomy for benign indications, with cefuroxime given to 4301 and metronidazole given to 2855. Excluding other antibiotics
Marcos Sande-Melón et al.
Cell reports, 29(4), 1041-1054 (2019-10-24)
During heart regeneration in the zebrafish, fibrotic tissue is replaced by newly formed cardiomyocytes derived from preexisting ones. It is unclear whether the heart is composed of several cardiomyocyte populations bearing different capacity to replace lost myocardium. Here, using sox10
Christina M Surawicz et al.
The American journal of gastroenterology, 108(4), 478-498 (2013-02-27)
Clostridium difficile infection (CDI) is a leading cause of hospital-associated gastrointestinal illness and places a high burden on our health-care system. Patients with CDI typically have extended lengths-of-stay in hospitals, and CDI is a frequent cause of large hospital outbreaks

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门